Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0018681 (headache)
 56,091 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

In 103 sexually mature women with disturbance of ovulation, a possible relationship between Kupperman menopausal complaints and endocrinological status was investigated to find the cause of climacteric syndrome. The Kupperman index was increased as the disturbance of ovulation was advanced from the stage of anovulatory cycle to amenorrhea I and further to amenorrhea II. In parallel with the advance in disturbance of ovulation, serum FSH and LH levels rose significantly, and serum estrone (E1) and estradiol (E2) levels dropped. Prolactin (PRL) showed a tendency to decrease. There were some hormonal patterns characteristic of individual complaints; hot flush was associated with increased FSH and LH, and decreased E1 and E2; difficulty in falling asleep, excitability, and fatigability, with increased FSH and LH, and decreased E2; nervousness, with increased LH and decreased E2; headache, with increased LH and PRL, and decreased E2; feeling of cold, with decreased E2 and PRL; and numbness and shoulder stiffness, with decreased E2. In sexually mature women, the complaints associated with abnormal levels of two or more kinds of hormones seemed to be most specifically related with decreased E2, followed by increased LH. Fatigability and headache developed specifically in the ovulatory phase of women with normal menstrual cycles (105 subjects), suggesting that these two complaints are closely related to increased LH. These results indicate that the majority of Kupperman menopausal complaints have their individually specific endocrinological cause, and that they may develop even in sexually mature women if those specific conditions exist. In climacteric syndrome in a narrow sense (i.e., dysautonomic type), each complaint may also have its specific endocrinological cause.
 ...
PMID:[Serum hormone level and Kupperman menopausal complaints in sexually mature women with disturbance of ovulation]. 391 22

A number of studies have been conducted to determine the effectiveness of veralipride (Agreal) in the treatment of the psycho-functional manifestations of menopause. All of these studies have obtained essentially similar results: very good effectiveness, in the order of 80 p. cent against hot flushes; very satisfactory effectiveness against the psycho-functional syndrome (50 to 70 p. cent). Headaches were the least affected by treatment (about 40 p. cent good results).
 ...
PMID:[Agreal: clinical experience. Review of the literature]. 399 11

One hundred and eighty-one patients with treated Parkinson's disease completed a self-administered questionnaire on symptoms, and their responses were compared with those of 263 control subjects randomly selected from a general practice population. Nine symptoms were reported by the patients with more than a fivefold excess when compared with the controls. These included jerking of the limbs, shaking of the hands, excessive salivation, poor mental concentration, grimacing, being frozen or rooted to the spot, and hallucinations. Compared with the general control population, the patients did not have an excess of stomach or limb pain, indigestion, headache, or any decrease of interest in sex. This observational survey, unlike a randomised controlled trial, could not ensure that the different treatment groups were comparable in important respects. However, certain associations were apparent; for example, patients receiving both a decarboxylase inhibitor and levodopa tended to report fewer attacks of being frozen to the spot, fewer problems with salivation, and a reduced frequency of defaecation. Patients receiving anticholinergic drugs reported an excess of dry mouth, faintness, and dyskinesia, and fewer hot flushes.
 ...
PMID:The symptoms of patients treated for Parkinson's disease. 400 65

Menopausal complaints, especially hot flushes, are common occurrences. Until now, no effective treatment was available for patients in whom estrogens are contraindicated. A trial of veralipride was carried out in ten symptomatic menopausal women (7 physiologic menopauses, 3 surgical menopauses). Symptoms included severe hot flushes, anxiety (N = 6), depression (N = 4), irritability (N = 3), and cephalalgia (N = 2). Patients were given one tablet of veralipride each day for twenty day periods. Effectiveness on hot flushes was excellent in six patients, satisfactory in two, mediocre in one, and null in one. Depression, anxiety, and, to a lesser extent, cephalalgia and irritability, were alleviated. No clinical or biological adverse side-effects were recorded.
 ...
PMID:[A clinical trial of veralipride in menopausal complaints (author's transl)]. 628 Mar 13

double-blind cross-over study with Org OD 14 was done in 35 post-menopausal patients aged 48-69 years who had hot flushes and other associated symptoms. Patients were randomly allocated to Org OD 14 or to placebo as first treatment. Each period of treatment lasted for 6 weeks and there were no intervals between treatments. Tablets containing 2.5 mg of Org OD 14 or placebo tablets of identical appearance were supplied. Patients took one Org OD 14 tablet or one placebo tablet per day. Data on the following variables were obtained and analyzed statistically: hot flushes, sweating, dizziness, palpitation, tiredness, headache, insomnia, irritability, breathlessness, backache, loss of libido, and mood. Assessment was daily in the case of hot flushes and weekly for the other variables. Org OD 14 was statistically significantly more effective in controlling hot flushes, sweating and headache and tended to be better than the placebo tablets for the other variables.
 ...
PMID:Double-blind cross-over study with Org OD 14 and placebo in postmenopausal patients. 666 Sep 26

A double-blind cross-over study with Org OD 14 and placebo was performed in 82 menopausal patients presenting with hot flushes and associated symptoms. Patients were randomly allocated to Org OD 14 or placebo as first treatment, and switched to placebo or Org OD 14 as second treatment. Each treatment period lasted for 16 weeks; no wash-out period was introduced. Tablets containing 2.5 mg of Org OD 14 or matched placebo tablets were supplied. Data on the following variables were obtained and analysed by the non-parametric randomization test for paired observations: hot flushes, sweating, dizziness, palpitations, fatiguability, headache, sleeplessness, irritability, breathlessness, backache and loss of libido and, in 16 patients, on circulating levels of FSH, LH, PRL, T3, T4, cortisol (F), SHBG, TBG and CBG. Twenty patients (13 placebo, 7 Org OD 14) withdrew, because their symptoms did not improve and one patient withdrew for reasons unrelated to treatment, so that 61 patients completed the study. The data demonstrated a good clinical effect and statistically significant differences in favour of Org OD 14 for hot flushes and a number of associated symptoms. Many patients reported on a general feeling of well being and a mood-elevating effect following Org OD 14. Org OD 14 significantly suppressed FSH and LH levels, while those of PRL remained unchanged. Although there was slight suppression of TBG and T4 which attained statistical significance, there was no influence on the most important parameter, T3. SHBG levels were slightly suppressed, whereas F and CBG levels were unaffected.
 ...
PMID:Placebo-controlled cross-over study of effects of Org OD 14 in menopausal women. 675 12

It has been suggested that women over age 40 use methods other than oral contraceptives (OCs) but there is evidence that the benefits of OCs should be weighed against the risks; some researchers have concluded that the existence of other predisposing risk factors is more important than age. Other hormonal methods available to middle aged women are: 1) continuous mini-progestogen OC which obviates the role of estrogens and are suggested for premenopausal women who do not show signs of hypoestrogenism, but pregnancy rate is still relatively high (3.0) for women aged 35 and over; 2) injectable contraceptives are believed to be highly effective but may depress some women; 3) estradiol pellet implants of 6-month intervals; in a group of 144 women aged 35-50 the pregnancy rate was 0.169; and 4) estradiol pellet implants with a 7-10 day course of an oral progestogen such as medroxyprogesterone acetate administered at monthly intervals to induce orderly withdrawal uterine bleeding; most common side effects are hypermenorrhea and mastodynia. The latter method is best suited to premenopausal women who wish to continue the low-dosage estrogen in advancing years, preventing the onset of hot flushes and sweats, minimizing the tendency to osteoporosis and decreasing the severity of menopausal migranoid headaches and mood changes.
 ...
PMID:Contraception for middle aged women. 676 1

Seventeen females with a history of hot flushes, perspiration, and amenorrhea of at least 6 months' duration, and a serum FSH level exceeding 40 IU/l entered a cyclic treatment with 17 beta-estradiol and estriol combined with norethsterone (Trisekvens, Novo). Each patient took part in three experimental sessions, six weeks apart, in which stress was induced by mental performance tests. To permit separation of treatment and habituation effects the patients were randomly assigned to one of two groups, Group 1 starting therapy after the first, Group 2 after the second session. Treatment eliminated hot flushes and perspiration and reduced serum FSH levels without causing changes in blood pressure or heart rate. There was no correlation between hormonal treatment and excretion of catecholamines during stress. Testosterone and androstenedione serum levels remained unchanged during therapy. Self-reports showed that tiredness, headache, tension and anxiety were significantly reduced following treatment.
 ...
PMID:Psychophysiological stress responses in postmenopausal women before and after hormonal replacement therapy. 718 90

Panic disorder is a chronic illness that affects at least 3 percent of the population. Panic disorder is associated with significant morbidity and an increased risk of suicide. Patients generally present with multiple somatic and psychologic complaints, including heart palpitations, chest pain, tremor, shortness of breath, choking, nausea or abdominal distress, dizziness, derealization, fear of losing control or going crazy, fear of dying, paresthesias, chills or hot flushes, headache, diarrhea, insomnia, chronic fatigue, anxiety and depression. To make the correct diagnosis, these symptoms must be evaluated carefully since they also occur with serious cardiovascular, pulmonary, endocrinologic and neurologic disorders. Many effective treatments are available, including tricyclic antidepressants, selective serotonin reuptake inhibitors, monoamine oxidase inhibitors, benzodiazepines such as alprazolam and clonazepam, and psychotherapy.
 ...
PMID:Panic disorder. 748 99

Six patients with symptomatic leiomyomata uteri and in whom surgical treatment was indicated received, during 3 months, intramuscular leuprolide acetate, 3,75 mg monthly, in order to 1) achieve a reduction of myomata size and 2) recover an anemic patient before surgery. In every patient, amenorrhea was induced since the second month of treatment. A significant decrease of myomas sizes was achieved. The reduction of the volume of the largest myoma in each case, varied between 51% and 77% (x = 60% +/- ES 4,3) LH and estradiol plasma levels diminished significantly and FSH did not changed in response to treatment. Side effects were well tolerated. Hot flashes were present in all patients, headaches in 2 and loss of strength in 2. Surgery was accomplished after 3 months of treatment. Myomectomy was performed in 5 cases and total hysterectomy in 1. Uterine shrinkage and the period of amenorrhea induced by Lupron-depot facilitated hysterectomy and myomectomy techniques and the recovery of one patient with a severe anemia.
 ...
PMID:[Size reduction of uterine myomas with monthly administered leuprolide acetate]. 756 60


<< Previous 1 2 3 4 5 6 7 8 9 Next >>